Marathon Asset Management Ltd lowered its holdings in shares of Envista Holdings Corporation (NYSE:NVST – Free Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 637,484 shares of the company’s stock after selling 61,962 shares during the period. Marathon Asset Management Ltd owned approximately 0.39% of Envista worth $13,840,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP grew its stake in Envista by 75.4% during the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after purchasing an additional 776 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after purchasing an additional 949 shares during the period. EverSource Wealth Advisors LLC grew its stake in Envista by 378.0% during the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock worth $47,000 after purchasing an additional 1,909 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Envista during the third quarter worth approximately $54,000.
Analysts Set New Price Targets
Several equities research analysts recently commented on NVST shares. Weiss Ratings cut Envista from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Stifel Nicolaus set a $31.00 price objective on Envista in a research note on Friday, February 6th. Citigroup initiated coverage on Envista in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price objective for the company. Robert W. Baird raised their price objective on Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. raised their price objective on Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.83.
Envista Stock Down 0.4%
Shares of NYSE:NVST opened at $23.07 on Wednesday. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of 56.26, a PEG ratio of 1.45 and a beta of 0.92. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. Envista Holdings Corporation has a 12-month low of $16.41 and a 12-month high of $30.42. The business’s 50 day moving average is $25.74 and its 200 day moving average is $24.26.
Envista (NYSE:NVST – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. The company had revenue of $705.50 million for the quarter, compared to analysts’ expectations of $680.04 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.Envista’s quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, sell-side analysts forecast that Envista Holdings Corporation will post 1.43 earnings per share for the current fiscal year.
Envista Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Featured Stories
- Five stocks we like better than Envista
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
